アペリス製薬は2025年第4四半期の収益予測を誤り,損失を報告し,前Q3の業績にかかわらず,収益が低下しました. Apellis Pharmaceuticals missed Q4 2025 earnings estimates, reported a loss, and saw revenue drop, despite prior Q3 beat.

アペリス製薬は2025年第4四半期に1株当たり0.47ドルの損失を報告し,0.08ドルの見積もりを欠き,売上高は前年比12.62億ドルの減少を記録した. Apellis Pharmaceuticals reported a fourth-quarter 2025 loss of $0.47 per share, missing estimates by $0.08, and saw revenue drop $12.62 million year-over-year. 同社は以前Q32025で期待を破り,株式の増加を招いた. The company had previously beat expectations in Q3 2025, driving a stock increase. 分析者は"Hold"コンセンサスを維持し,平均価格目標は33.00ドルであり,1月22日にインサイダー販売が記録された. Analysts maintain a "Hold" consensus with a $33.00 average price target, while insider sales were noted on January 22. 株式の市場資本額は28億4千万ドルで,12ヶ月間は16.10ドルから30.48ドルまで取引されています. The stock trades with a market cap of $2.84 billion and a 12-month range of $16.10 to $30.48.